Julie Ince – Demetriou, Executive Director, Research at National Breast Cancer Foundation, CEO shared Molecule 2 Market’s post on LinkedIn, adding:
“I’m delighted to step into the CEO role at Molecule 2 Market at such a pivotal point in the organisation’s journey. As we enter our next chapter of growth and scale, I’m excited to work alongside our talented team, Board and partners to continue building on the strong foundation that has been created.
Molecule 2 Market has established a strong reputation for scientific excellence, integrity and a deeply client‑centred approach. I’m energised by the opportunity to help guide the organisation through its next phase, strengthening our collaborative, partnership‑driven model to deliver exceptional value, foster innovation and ultimately enable even greater healthcare impact through the advancement of therapies that benefit patients.
I’d also like to acknowledge Anne De Luca and Robin Hansen for their passion, leadership and vision that have brought Molecule 2 Market to this point. I’m excited to work closely together as we begin this next chapter and continue expanding our impact across the life sciences ecosystem.”
Quoting Molecule 2 Market’s post:
“As the organisation enters its next phase of growth and scale, Molecule2Market is delighted to announce the appointment of Dr Julie Ince – Demetriou as Chief Executive Officer.
This appointment reflects both the ambition of the business and the increasing complexity of its day – to – day operations. Julie brings deep clinical research expertise, strong strategic leadership, and a proven track record of translating strategy into execution. She is recognised for building high – performing teams, scaling organisations sustainably, and fostering collaborative partnerships across the life sciences ecosystem.
The CEO role has been established to provide focused, full – time leadership across Molecule2Market’s operations, growth, and external partnerships, ensuring continued momentum as the organisation expands.
Directors Anne De Luca and Robin Hansen will remain highly engaged and actively involved in governance, strategic direction, and long – term vision, and will continue to work closely with Julie as Molecule2Market enters this next chapter.
‘Bringing a CEO on board is a natural evolution for the organisation. It strengthens our leadership structure while ensuring the values, vision, and intent that shaped the business from the beginning remain firmly in place.’
— Robin Hansen
‘What stood out about Julie was her ability to combine commercial acumen with strong people leadership. As we scale, maintaining our culture is just as important as maintaining momentum. Julie’s values align strongly with everything Molecule2Market stands for, and we are confident she will continue to drive the organisation forward while valuing and empowering our team.’
— Anne De Luca
‘I’m excited to step into the CEO role at such a pivotal time for Molecule2Market. The organisation has built a strong reputation for scientific excellence and integrity, and I’m looking forward to working closely with our talented team, Board and clients to drive the next phase of growth and impact.’
— Dr Julie Ince – Demetriou, PhD”
More posts featuring Julie Ince – Demetriou